POS0814 OUTCOME OF VASCULAR INVOLVEMENT OF BEHÇET’S SYNDROME TREATED WITH INFLIXIMAB: A RETROSPECTIVE COHORT STUDY

Background Vascular involvement is the most common cause of mortality and an important disability in patients with Behçet’s syndrome (BS). Cyclophosphamide has been treatment choice for severe vascular involvement, but high frequency adverse events such as infertility infections concern. TNF inhibitors can be alternative BS involvement. Objectives To survey efficacy safety infliximab (IFX) arterial venous Methods We reviewed charts who used IFX extracted data on demographic clinical features, type laboratory tests, imaging modalities, concomitant immunosuppressives, duration use, outcome. The primary endpoint was remission, defined presence all following 3 parameters: 1) lack new symptoms/findings associated lesion 2) normalization CRP level <10 mg/dl) 3) worsening or a at another site imaging. Remission assessed month 6 12. Secondary endpoints were relapse, overall disease activity BDCAF baseline final visit, development organ other than during treatment, leading to discontinuation therapy, hospitalization death, death. Results Among 371 between 2004 June 2021, 127 (102 men, 25 women, mean age 40 ± 8.7 years) had it types that required thrombosis 61 (48%), pulmonary artery 37 (29%), non-pulmonary 16 (13%), ulcer 13 (10%). rate 72% (92/127) 61% (71/117) 17/99 (17%) experienced 22 relapses follow-up 28.4±21 months therapy. relapses, 12 progression pre-existing 10 lesions. Overall improved decrease score from 1.76 1.27 0.6 0.8 visit (p<0.001). relapse rates according causes are presented Table 1. Adverse infusion reactions 5, tuberculosis, disseminated zona, lung adenocarcinoma, fibromyxoid sarcoma, heart failure, SLE, palmoplantar pustulosis, auricular chondritis, aortic stent graft infection 1 patient each. immunosuppressive use outcomes treated Venous (n=61) Pulmonary (n=37) Non-pulmonary (n=16) ulcers (n=13) (n=127) Number immunosuppressives 48 (79) 24 (65) 14 (87) 7 (54) 93 (73) Duration (mean SD months) 19.7 19.3 35 29.6 26 21 50 (82) 31 (84) (63) (8) 92 (72) (70) (64) 8 (53) 2 (17) 71 (60) Relapse 4 (7) (11) 9 0 17 (13) discontinued (51) 23 (62) 5 (31) (69) 68 Due remission 15 inefficacy 11 event noncompliance reasons b Death Since did not reach 12th yet, percentages calculated 117 patients. Other preparation surgical operation (n=2), wanting come frequently pandemic pregnancy (n=1), willing get pregnant health insurance due prison sentence death (n=1). Conclusion Infliximab may beneficial even those refractory corticosteroids. Disclosure Interests Gulen Hatemi Speakers bureau: served speaker AbbVie, Celgene, Novartis, UCB Pharma, Grant/research support from: received grant/research Beyza Tukek: None declared, Sinem Nihal Esatoglu honorariums presentations Roche, Pfizer, Merck Sharp Dohme., Yesim Ozguler Pfizer., Sitki Safa Taflan: Melike Melikoglu: Serdal Ugurlu: Izzet Fresko: Zekayi Kutlubay: Sebahattin Yurdakul: Hasan Yazici: Vedat Hamuryudan Celgene.